ILiAD Biotechnologies closed an oversubscribed $115 million Series B to accelerate its whooping cough vaccine programs toward pivotal trials and Phase 3 accrual. The financing aims to fund expanded clinical development and manufacturing scale‑up for its next‑generation vaccine candidate. Generate Biomedicines filed for an IPO days after dosing the first patient in Phase III for its AI‑designed antibody GB‑0895 in severe asthma. The company said proceeds will support completion of two Phase III trials and broaden development into COPD and other respiratory indications, highlighting investor appetite for AI‑programmed biologics.